Back
Halozyme Therapeutics Quote, Financials, Valuation and Earnings
Buy
75
HALO
Halozyme Therapeutics
Last Price:
44.73
Seasonality Move:
1.35%
7 Day Trial
ALL ACCESS PASS
$
7
Halozyme Therapeutics Price Quote
$44.73
+0.02 (+-1.45%)
(Updated: May 18, 2024 at 5:45 AM ET)
Halozyme Therapeutics Key Stats
Buy
75
Halozyme Therapeutics (HALO)
is a Buy
Day range:
$44.35 - $45.76
52-week range:
$31.86 - $46.16
Dividend yield:
0%
P/E ratio:
21.29
P/S ratio:
6.83
P/B ratio:
32%
Volume:
1.1M
Avg. volume:
972.7K
1-year change:
33.62%
Market cap:
$5.7B
Revenue:
$829.3M
EPS:
$2.42
How Much Does Halozyme Therapeutics Make?
-
How Much Are Halozyme Therapeutics's Sales Annually?
HALO Revenues are $829.3M -
How Much Profit Does Halozyme Therapeutics's Make A Year?
HALO net income is $281.6M
Is Halozyme Therapeutics Growing As A Company?
-
What Is Halozyme Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is 0.21% -
What Is Halozyme Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 1.07%
Halozyme Therapeutics Stock Price Performance
-
Did Halozyme Therapeutics Stock Go Up Last Month?
Halozyme Therapeutics share price went up by 17.6% last month -
Did HALO's Share Price Rise Over The Last Year?
HALO share price rose by 33.62% over the past 1 year
What Is Halozyme Therapeutics 52-Week High & Low?
-
What Is Halozyme Therapeutics’s 52-Week High Share Price?
Halozyme Therapeutics has traded as high as $46.16 over the past 52 weeks -
What Is Halozyme Therapeutics’s 52-Week Low Share Price?
Halozyme Therapeutics has traded as low as $31.86 over the past 52 weeks
Halozyme Therapeutics Price To Free Cash Flow
-
Is Halozyme Therapeutics Stock Overvalued?
Halozyme Therapeutics is trading at a price to free cash flow ratio of 13.92 -
Is Halozyme Therapeutics Stock Undervalued?
Halozyme Therapeutics EV to Free Cash Flow ratio is 15.88 -
What Is Halozyme Therapeutics’s Price Earnings Growth Ratio?
HALO PEG ratio is 0.22 -
Is Halozyme Therapeutics Trading At A Premium To Earnings?
Halozyme Therapeutics EV to EBIT ratio is 16.38
Is It Risky To Buy Halozyme Therapeutics?
-
How Much Debt Does Halozyme Therapeutics Have?
Total long term debt quarterly is $1.5B -
How Much Cash Does Halozyme Therapeutics Have?
Cash and short term investments quarterly total is $463.5M -
What Is Halozyme Therapeutics’s Book Value Per Share?
Book value per share is 1.40
Is Halozyme Therapeutics Cash Flow Positive?
-
What Is HALO Cash Flow From Operations?
Cash flow from operations (TTM) is $431M -
What Is Halozyme Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is -$243.9M -
What Is Halozyme Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is -$119.4M
Halozyme Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
HALO return on invested capital is 19.4% -
What Is Halozyme Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is 17.76% -
What Is HALO Return On Equity?
ROE is a measure of profitability and is 219.05%
Halozyme Therapeutics Earnings Date & Stock Price
-
What Is Halozyme Therapeutics's Stock Price Today?
A single share of HALO can be purchased today for 44.71 -
What Is Halozyme Therapeutics’s Stock Symbol?
Halozyme Therapeutics trades on the nasdaq under the ticker symbol: HALO -
When Is Halozyme Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Halozyme Therapeutics is scheduled on August 8, 2024 -
When Is HALO's next ex-dividend date?
Halozyme Therapeutics's next ex-dividend date is May 20, 2024 -
How To Buy Halozyme Therapeutics Stock?
You can buy Halozyme Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Halozyme Therapeutics Competitors
-
Who Are Halozyme Therapeutics's Competitors?
Below is a list of companies who compete with Halozyme Therapeutics or are related in some way:
Halozyme Therapeutics Dividend Yield
Data Unavailable
Halozyme Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 106.9% | 13.57% |
| Revenue: | 20.81% | -1.89% |
Analyst Recommendations
| Buy Recommendations: | 2 |
|---|---|
| Hold Recommendations: | 2 |
| Sell Recommendations: | 0 |
| Price Target: | 51.44 |
| Upside from Last Price: | 15.06% |